Sökning: "blood coagulation"
Visar resultat 1 - 5 av 184 avhandlingar innehållade orden blood coagulation.
1. Inflammation and immunothrombosis in cerebral cavernous malformation : Novel molecular targets for the treatment of an incurable disease
Sammanfattning : Cerebral cavernous malformation (CCM) is a vascular disease that causes mulberry-like lesions (cavernomas) in the central nervous system (CNS). Cavernomas are fragile, leaky and prone to rupture which may cause symptoms such as epileptic seizures, focal neurological deficits and hemorrhagic strokes. CCM lesions can appear sporadically in 0. LÄS MER
2. Dissertatio de haemorrhoea, quam venia ... ord. med. Upsal. præside Joh. Gust. Acrel ... pro gradu doctoris publicæ defert censuræ Carolus Zetterström ... Jemtlandus. In audit. Gust. maj. d. XIII Maji MDCCXCVII. Horis a. et p. meridiem solitis
Sammanfattning : .... LÄS MER
3. Historia febris intermittentis petechialis, qvam venia ... med. ord. Ups. præside Joh. Gust. Acrel ... pro gradu doctoris publice ventilandam sistit Joh. Sigfr. Schedvin, Dalecarlus. In audit. Gust. maj. d. XXVII Apr. MDCCXCIII. Horis a. et p. meridiem solitis
Sammanfattning : .... LÄS MER
4. Synthesis, Function, and Inactivation of Blood Coagulation Factor V
Sammanfattning : Blood coagulation factor V (FV) is a 330 kDa plasma glycoprotein. Activated FV (FVa) is a non-enzymatic cofactor to activated Factor X in the activation of prothrombin that occurs during coagulation. LÄS MER
5. Regulation of Tissue Factor and Coagulation Activity : Translation Studies with Focus on Platelet-Monocyte Aggregates and Patients with Acute Coronary Syndrome
Sammanfattning : Myocardial infarction (MI) is often caused by a disruption of an atherosclerotic plaque with activation of coagulation, platelets and inflammation. The aims were; to investigate whether the oral direct thrombin inhibitor, ximelagatran affected markers for coagulation, platelet and inflammation in a patient cohort with recent MI and if the coagulation markers could identify patients with increased risk of new ischemic events; to evaluate some of the mechanisms involved in formation of platelet-monocyte aggregates (PMAs). LÄS MER